Expert Interview
A Second Look: Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy
Ticker(s): KPTIInstitution: MSKCC
- Attending physician at MSKCC, Gynecologic Oncologist & Early Drug Development Specialist
- Primary interest is caring for women with ovarian cancer, endometrial cancer, cervical cancer, and other gynecologic cancers and researching these diseases.
- Served on the steering committee for the Society for Gynecologic Oncology and on the medical oncology committee of the Gynecologic Oncology Group.
How many endometrial cancer patients do you treat?
Added By: wilson_adminWhat is your impression of selinexor safety profile?
Added By: wilson_adminHow confident are you in the results of the subgroup analysis?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
